All relevant data are within the paper and its Supporting Information files.

Background {#sec004}
==========

In addition to emergency coronary revascularization *via* percutaneous coronary intervention (PCI) or cardiac surgery, treatment of acute coronary syndrome (ACS) includes dual antiplatelet therapy in which aspirin is combined with a P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor). For several years now, ticagrelor has been recommended over clopidogrel in the absence of contraindications, due to greater efficacy and speed of action, even though an increased risk of bleeding has been reported in several cardiology studies \[[@pone.0232768.ref001]--[@pone.0232768.ref004]\].

The most severe cases of ACS require intensive care management, especially in the presence of shock and/or severe respiratory distress. This is an important issue given that the percentage of ACS patients with Killip class IV (*i*.*e*. cardiogenic shock) reported in the literature is significant, ranging from 1 to 12% \[[@pone.0232768.ref005]--[@pone.0232768.ref007]\]. In fact, intensive care management of critically ill ACS patients often requires invasive techniques that can cause bleeding (central venous catheter, arterial catheter, mechanical ventilation, renal replacement therapy, circulatory assistance, etc.). To our knowledge, no study to date has examined the risk of bleeding in Intensive Care Unit (ICU) patients with ACS treated with ticagrelor. The primary objective of this study was to compare the bleeding risk of ticagrelor and clopidogrel in ICU patients diagnosed with ACS.

Methods {#sec005}
=======

This retrospective study was approved by the Institutional Review Board of the Ethics Committee of Reunion Island University Hospital (reference R15007). The need for informed consent was waived because of the observational and retrospective nature of the study. This article follows the STROBE reporting guidelines for observational studies \[[@pone.0232768.ref008],[@pone.0232768.ref009]\].

Study population {#sec006}
----------------

We conducted a retrospective observational study in a 23-bed medical-surgical adult ICU in a French university hospital. This university hospital is the regional reference center for the management of patients with ACS and/or cardiogenic shock. It includes a technical center open 24/7, which offers coronary angiography, extracorporeal life support (ECLS), and cardiac surgery services. As the study was designed following the introduction of ticagrelor in our institution in 2012, the inclusion period was from January 2013 to January 2017. We retrospectively analyzed the medical records of all patients with ACS who were hospitalized in our ICU during the inclusion period. Exclusion criteria were: age below 18 years, treatment of ACS with cardiac surgery, treatment of ACS with thrombolysis and/or prasugrel, and incomplete/lost medical record. Patients could be included in the study only once, and the analysis focused on the first ACS-related stay in ICU.

During the study period, a regional protocol for the management of patients with ACS in the emergency department or outside hospital was designed based on European recommendations \[[@pone.0232768.ref010]\]. Accordingly, the treatment of STEMI, administered prior to PCI, was composed of: (*i*) intravenous aspirin (250 mg) and (*ii*) ticagrelor (180 mg) or clopidogrel (600 mg), the former being preferred in the absence of contraindications (*i*.*e*., history of hemorrhagic stroke, severe hepatic insufficiency, chronic hemodialysis, ongoing anticoagulant treatment) and (*iii*) intravenous enoxaparin (0.5 mg.kg^-1^) or, in cases of severe chronic renal failure, unfractionated heparin (bolus of 70 UI.kg^-1^, and then 12 UI.kg^-1^.h^-1^). Thrombolysis was administered when PCI could not be performed within 120 minutes of ACS onset. Ticagrelor and clopidogrel were administered in ICU at a dose of 90 mg twice daily and 75 mg daily, respectively.

Data collection and processing {#sec007}
------------------------------

Demographic data, test results, therapeutics used, and patient progress before and during ICU stay were analyzed. Time of inclusion was defined by the date of initiation of treatment with clopidogrel or ticagrelor. The primary outcome was bleeding occurrence during ICU stay according to the Thrombolysis in Myocardial Infarction (TIMI) criteria which have been used in most cardiovascular trials and recommendations for the past thirty years \[[@pone.0232768.ref002],[@pone.0232768.ref004],[@pone.0232768.ref005],[@pone.0232768.ref010],[@pone.0232768.ref011]\].

Bleeding was classified as TIMI major or minor; we did not record the TIMI minimal. In case of multiple bleeding in the same patient, the most severe TIMI bleeding event was recorded. The secondary outcomes were ICU mortality, ICU length of stay, and other markers of bleeding such as blood transfusion.

Definitions {#sec008}
-----------

ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina were defined according to the European Society of Cardiology guidelines for the management of ACS \[[@pone.0232768.ref012]\].

Cardiogenic shock was defined by: systolic blood pressure \< 90 mm Hg for more than 30 minutes, need for vasopressors to achieve systolic blood pressure \> 90 mm Hg, pulmonary congestion, elevated left ventricular filling pressure (*i*.*e*. pulmonary capillary wedge pressure \> 18 mmHg), reduced cardiac index (\< 1.8 L.min^-1^.m^-2^ without support and 2.0--2.2 L.min^-1^.m^-2^ with support), and/or signs of impaired organ perfusion as manifested by one of the following: *i*) altered mental status, *ii*) cold, clammy skin and extremities, *iii*) oliguria with urine output \< 30 mL.hour^-1^, *iv*) serum lactate \> 2.0 mmol.L^-1^ \[[@pone.0232768.ref013]\].

In accordance with the TIMI classification, major bleeding was defined as: *i*) any intracranial bleeding (excluding microhemorrhages \<10 mm evident only on gradient-echo magnetic resonance imaging) or *ii*) clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥ 5 g.dL^-1^ or a 15% absolute decrease in hematocrit or *iii*) fatal bleeding (bleeding that directly results in death within 7 days). Minor bleeding was defined as: *i*) any clinically overt sign of hemorrhage (including imaging) associated with a drop in hemoglobin of 3 to \< 5 g.dL^-1^ or a 10% to 15% decrease in hematocrit or *ii*) no observed blood loss, *i*.*e*., a drop in hemoglobin of 4 g.dL^-1^ to \< 5 g.dL^-1^ or a 12% to 15% decrease in hematocrit. Minimal bleeding was any overt sign of hemorrhage that did not meet the criteria for major or minor bleeding defined above and that met one of the following criteria: *i*) requiring intervention (medical practitioner-guided medical or surgical treatment to stop or treat bleeding, including temporarily or permanently discontinuing or changing the dose of a medication or study drug), *ii*) leading to or prolonging hospitalization, *iii*) prompting evaluation (leading to unscheduled visit to a healthcare professional and diagnostic testing, either laboratory or imaging) \[[@pone.0232768.ref014]\].

Statistical analysis {#sec009}
--------------------

Results were expressed as frequencies and percentages for categorical variables, and as median and interquartile range for continuous variables. Categorical variables were compared using chi-square test or Fisher's exact test, as appropriate. Continuous variables were compared using Student's t-test or Mann-Whitney U test, as appropriate.

Propensity score {#sec010}
----------------

Propensity score was defined as the probability of exposure to ticagrelor. To limit over adjustment which might result from using this score, we selected only the covariates likely to introduce a confounding bias \[[@pone.0232768.ref015],[@pone.0232768.ref016]\].

The propensity score was estimated using a logistic regression adjusted for age, gender, place of initial care, history of chronic renal failure and/or hypertension and/or heart failure, and usual treatment with clopidogrel and/or ticagrelor and/or aspirin. Matching was then performed between patients exposed to ticagrelor and unexposed patients with a propensity score caliper of 0.05. After propensity score matching, standardized differences were estimated to compare baseline characteristics and, therefore, to assess the accuracy of the matching procedure.

Analysis of outcomes {#sec011}
--------------------

Cumulative incidence of bleeding was modeled using a proportional hazards model for the subdistribution of a competing risk, for clustered data \[[@pone.0232768.ref017],[@pone.0232768.ref018]\]. Death was the only competing risk considered. The proportional hazards model was stratified by group of patients defined by propensity score matching. Hazard ratios and their 95% confidence intervals (CI) were calculated. A two-tailed *p* value \< 0.05 was considered significant.

Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA) and R (package crrSC v1.1).

Results {#sec012}
=======

Over the study period, 230 patients were hospitalized in ICU with a diagnosis of ACS. Of these, 75 were excluded from the study (35 patients received thrombolysis, 34 patients received cardiac surgery, 4 patients received prasugrel, and 2 patients had incomplete or lost medical records). A total of 155 patients were included in the study. Using propensity score matching, 57 patients were included in the clopidogrel group and 57 were included in the ticagrelor group **([Fig 1](#pone.0232768.g001){ref-type="fig"}**).

![Flow chart of the study, illustrating the matched groups according to propensity score.](pone.0232768.g001){#pone.0232768.g001}

Characteristics of the 155 included patients (before matching) {#sec013}
--------------------------------------------------------------

The characteristics of the 155 included patients at study inclusion and between study inclusion and ICU discharge or death are compared in [S1 Table](#pone.0232768.s001){ref-type="supplementary-material"} and [S2 Table](#pone.0232768.s002){ref-type="supplementary-material"}. Median age was 65.0 (55.8--73.0) years old. During the study period, all patients were treated with aspirin, 82 patients (52.9%) were treated with ticagrelor and 73 (47.1%) were treated with clopidogrel. Comparison of patients treated with ticagrelor and patients treated with clopidogrel at study inclusion showed mainly differences in age, presence of hypertension or chronic renal failure, and usual treatment with clopidogrel Significant differences in SAPS II, renal failure, and initial treatment were observed between study inclusion and ICU discharge or death.

Characteristics of the 114 matched patients {#sec014}
-------------------------------------------

According to propensity score matching, 57 patients treated with ticagrelor were matched with 57 patients treated with clopidogrel.

No significant differences in patient characteristics at study inclusion were found between the ticagrelor group and the clopidogrel group, as shown in **[Table 1](#pone.0232768.t001){ref-type="table"}**.

10.1371/journal.pone.0232768.t001

###### Characteristics of the 114 matched patients at study inclusion.

![](pone.0232768.t001){#pone.0232768.t001g}

  Variables                                                  All patients (*n* = 114)   Clopidogrel (*n* = 57)   Ticagrelor (*n* = 57)   Standardized difference
  ---------------------------------------------------------- -------------------------- ------------------------ ----------------------- -------------------------
  Age (years)                                                65.4 (56.1--73.0)          65.8 (56.4--73.1)        65.1 (56.1--71.9)       0.00
  Male gender                                                83 (72.8%)                 42 (73.7%)               41 (71.9%)              -0.04
  History of                                                                                                                             
      Hypertension                                           75 (65.8%)                 40 (70.2%)               35 (61.4%)              -0.18
      Diabetes mellitus                                      66 (57.9%)                 35 (61.4%)               31 (54.4%)              -0.14
      Smoking (current or former)                            64 (56.1%)                 28 (49.1%)               36 (63.2%)              0.28
      Dyslipidemia                                           39 (34.2%)                 21 (36.8%)               18 (31.6%)              -0.11
      Chronic heart failure                                  35 (30.7%)                 19 (33.3%)               16 (28.1%)              -0.11
      Coronary artery disease                                31 (27.2%)                 16 (28.1%)               15 (26.3%)              -0.04
      Peripheral artery occlusive disease                    18 (15.8%)                 9 (15.8%)                9 (15.8%)               0.00
      Chronic renal failure                                  14 (12.3%)                 7 (12.3%)                7 (12.3%)               0.00
      Ischemic stroke                                        11 (9.6%)                  7 (12.3%)                4 (7.0%)                -0.18
      Body mass index \> 30kg.m^-2^                          11 (9.6%)                  7 (12.3%)                4 (7.0%)                -0.18
      Sleep apnea syndrome                                   8 (7.0%)                   3 (5.3%)                 5 (8.8%)                0.14
      Cancer                                                 7 (6.1%)                   4 (7.0%)                 3 (5.3%)                -0.07
      Chronic obstructive pulmonary disease                  7 (6.1%)                   3 (5.3%)                 4 (7.0%)                0.07
      Hazardous alcohol use                                  2 (1.8%)                   1 (1.8%)                 1 (1.8%)                0.00
  Usual treatment                                                                                                                        
      Oral anticoagulant                                     3 (2.6%)                   2 (3.5%)                 1 (1.8%)                -0.11
      Aspirin                                                44 (38.6%)                 22 (38.6%)               22 (38.6%)              0.00
      Clopidogrel                                            19 (16.7%)                 11 (19.3%)               8 (14.0%)               -0.14
      Ticagrelor                                             2 (1.8%)                   1 (1.8%)                 1 (1.8%)                0.00
  Place of initial care                                                                                                                  -0.13
      Outside hospital                                       68 (59.6%)                 32 (56.1%)               36 (63.2%)              0.14
      In hospital, emergency department                      24 (21.1%)                 13 (22.8%)               11 (19.3%)              
      In hospital, other department                          22 (19.3%)                 12 (21.1%)               10 (17.5%)              
  Cardiac arrest before ICU admission                        53 (46.5%)                 28 (49.1%)               25 (43.9%)              -0.10
  Type of ACS : STEMI[\*](#t001fn002){ref-type="table-fn"}   88 (77.2%)                 42 (73.7%)               46 (80.7%)              0.17

Results are expressed as median (first and third quartile) and numbers (proportions). ACS: Acute coronary syndrome; ICU: Intensive Care Unit; STEMI: ST-segment elevation myocardial infarction.

\*opposite to "non-ST-segment elevation myocardial infarction".

The characteristics of matched patients treated with ticagrelor or clopidogrel between study inclusion and ICU discharge or death are compared in **[Table 2](#pone.0232768.t002){ref-type="table"}**. Patients treated with ticagrelor had a significantly lower SAPS II than patients treated with clopidogrel (60.0 (38.0--80.0) *vs*. 69.0 (46.0--88.0), *p* = 0.03). While there were no significant differences in dobutamine or norepinephrine use between the two groups, epinephrine use in the first 24 hours after admission to ICU was significantly rarer in the ticagrelor group than in the clopidogrel group (14% *vs*. 31.6%, *p* = 0.03). Coronary angiography was performed in 108 patients (94.7%), and ≥1 coronary stent(s) were implanted in 90 patients (83.3%). Glycoprotein IIb/IIIa inhibitors (tirofiban) were used in 36 patients (31.6%), with no significant difference between the two groups. No significant differences in specific treatment for ACS were observed between the two groups. Creatinine levels, alanine and aspartate aminotransferase, prothrombin, and activated partial thromboplastin time at ICU admission were abnormal in both groups with no significant differences between the two groups. No significant differences in biological and clinical parameters and other treatments were found between the two groups.

10.1371/journal.pone.0232768.t002

###### Characteristics and outcomes of the 114 matched patients between study inclusion and ICU discharge or death.

![](pone.0232768.t002){#pone.0232768.t002g}

  Variables                                                 All patients (*n* = 114)   Clopidogrel (*n* = 57)   Ticagrelor (*n* = 57)   *P value*
  --------------------------------------------------------- -------------------------- ------------------------ ----------------------- -----------
  Coronary angiography                                      108 (94.7%)                52 (91.2%)               56 (98.2%)              0.21
  Stent                                                     90 (83.3%)                 43 (82.7%)               47 (83.9%)              0.86
  ECLS during coronary angiography                          5 (4.4%)                   3 (5.3%)                 2 (3.5%)                1.00
  Emergency care initiated for ACS                                                                                                      
      Glycoprotein IIb/IIIa inhibitors (tirofiban)          36 (31.6%)                 14 (24.6%)               22 (38.6%)              0.11
      Aspirin                                               114 (100.0%)               57 (100.0%)              57 (100.0%)             NA
      Low Molecular Weight Heparin                          94 (82.5%)                 45 (78.9%)               49 (85.9%)              0.32
      Unfractionated Heparin                                20 (17.5%)                 12 (21.0%)               8 (14.0%)               0.32
  At ICU admission                                                                                                                      
      Simplified Acute Physiology Score II                  61.5 (41.0--85.0)          69.0 (46.0--88.0)        60.0 (38.0--80.0)       0.03
      Therapeutic hypothermia                               1 (0.9%)                   0 (0.0%)                 1 (1.8%)                1.00
      Left ventricular ejection fraction                    0.3 (0.2--0.5)             0.3 (0.2--0.4)           0.4 (0.3--0.5)          0.11
  Biological parameters at ICU admission                                                                                                
      Hemoglobin level (g.dL^-1^)                           12.3 (10.5--13.7)          12.4 (10.5--13.7)        12.2 (10.6--13.7)       0.89
      Platelet count (G.L^-1^)                              227.0 (188.0--274.0)       219.5 (171.0--265.0)     239.0 (207.0--276.0)    0.29
      aPTT (ratio)                                          1.6 (1.3--3.5)             1.5 (1.3--3.0)           2.1 (1.3--3.5)          0.95
      Prothrombin (%)                                       68.0 (55.0--76.0)          67.0 (55.0--74.0)        69.5 (56.0--76.0)       0.40
      Urea (mmol.L^-1^)                                     7.9 (5.2--13.2)            9.3 (5.9--15.0)          7.2 (4.8--10.6)         0.34
      Creatinine (μmol.L^-1^)                               123.0 (86.0--212.0)        142.0 (101.0--230.0)     110.5 (76.5--176.5)     0.18
      Aspartate aminotransferase (UI.L^-1^)                 135.0 (49.0--323.0)        124.0 (43.0--284.0)      153.5 (56.5--333.0)     0.08
      Alanine aminotransferase (UI.L^-1^)                   53.0 (33.0--113.0)         60.0 (37.0--119.0)       51.0 (31.0--111.0)      0.05
  During ICU stay                                                                                                                       
      Epinephrine within 24 hours of admission              26 (22.8%)                 18 (31.6%)               8 (14.0%)               0.03
      Norepinephrine within 24 hours of admission           62 (54.4%)                 31 (54.4%)               31 (54.4%)              1.00
      Dobutamine within 24 hours of admission               43 (37.7%)                 19 (33.3%)               24 (42.1%)              0.33
      Mechanical ventilation within 24 hours of admission   100 (87.7%)                50 (87.7%)               50 (87.7%)              1.00
      ECLS                                                  15 (13.2%)                 9 (15.8%)                6 (10.5%)               0.41
          ECLS Delay after ICU admission (days)             1.0 (0.0--1.0)             1.0 (0.0--1.0)           0.5 (0.0--1.0)          0.69
      Central venous catheter                               101 (88.6%)                50 (87.7%)               51 (89.5%)              0.77
      Dialysis catheter                                     31 (27.2%)                 17 (29.8%)               14 (24.6%)              0.53
      Electrical pacing                                     6 (5.3%)                   4 (7.0%)                 2 (3.5%)                0.68
      Arterial catheter (excluding angiography catheter)    97 (85.1%)                 50 (87.7%)               47 (82.5%)              0.43
      Intra-aortic balloon pump                             17 (14.9%)                 11 (19.3%)               6 (10.5%)               0.19
      Proton pump inhibitor                                 108 (94.7%)                55 (96.5%)               53 (93.0%)              0.40
  Outcomes during ICU stay                                                                                                              
      TIMI major or minor bleeding                          47 (41.2%)                 12 (21.1%)               35 (61.4%)              \<0.0001
          Delay after ICU admission (days)                  1.0 (0.0--2.0)             0.0 (0.0--1.0)           1.0 (1.0--3.0)          0.009
      TIMI major bleeding                                   27 (23.7%)                 7 (12.3%)                20 (35.1%)              0.004
      TIMI minor bleeding                                   20 (17.5%)                 5 (8.8%)                 15 (26.3%)              0.01
      Minimum hemoglobin level (g.dL^-1^)                   9.1 (7.7--11.2)            10.2 (8.2--12.0)         8.5 (7.2--10.5)         0.009
      Hemoglobin variation since admission (g.dL^-1^)       -2.0 (-4.1 ---0.8)         -1.5 (-2.6 ---0.5)       -3.2 (-5.2 ---1.5)      0.009
      Red blood cell transfusion                            38 (33.3%)                 14 (24.6%)               24 (42.1%)              0.04
      Total red blood cell transfusion (units)              0.0 (0.0--2.0)             0.0 (0.0--0.0)           0.0 (0.0--4.0)          0.02
      Platelet transfusion                                  7 (6.1%)                   2 (3.5%)                 5 (8.8%)                0.24
      Total platelet transfusion (units)                    0.0 (0.0--0.0)             0.0 (0.0--0.0)           0.0 (0.0--0.0)          0.20
      Plasma transfusion                                    6 (5.3%)                   3 (5.3%)                 3 (5.3%)                1.0
      Total plasma transfusion (units)                      0.0 (0.0--0.0)             0.0 (0.0--0.0)           0.0 (0.0--0.0)          0.91
  ICU length of stay (days)                                 4.0 (3.0--8.0)             3.0 (2.0--7.0)           4.0 (3.0--9.0)          0.19
  Death in ICU                                              43 (37.7%)                 26 (45.6%)               17 (29.8%)              0.08

Results are expressed as median (first and third quartile) and numbers (proportions). ACS: Acute coronary syndrome; aPTT: Activated partial thromboplastin time; ECLS: Extracorporeal life support; ICU: Intensive Care Unit; NA: Not applicable; STEMI: ST-segment elevation myocardial infarction.

Outcomes of the 114 matched patients {#sec015}
------------------------------------

The primary and secondary outcomes of matched patients treated with ticagrelor and clopidogrel are summarized in **[Table 2](#pone.0232768.t002){ref-type="table"}**. Bleeding was observed in 47 patients (41.2%), with TIMI major bleeding occurring in 27 patients (23,7%) and TIMI minor bleeding occurring in 20 patients (17,5%). Of the 47 patients with bleeding, 12 (21.1%) were treated with clopidogrel and 35 (61.4%) with ticagrelor (*p*\< 0.0001). This significant association was found for both TIMI major bleeding (12.3% *vs*. 35.1%, *p* = 0.004) and TIMI minor bleeding (8.8% *vs*. 26.3%, *p* = 0.01).

Hemoglobin levels at ICU admission were not significantly different between the ticagrelor group and the clopidogrel group (12.2 (10.6--13.7) *vs*. 12.4 (10.5--13.7) g.dL^-1^, *p* = 0,89). However, during ICU stay, patients treated with ticagrelor had lower minimal hemoglobin levels (8.5 (7.2--10.5) *vs*. 10.2 (8.2--12.0) g.dL^-1^, *p* = 0.009), a greater variation in hemoglobin levels (-3.2 (-5.2 ---1.5) *vs*. -1.5 (-2.6 ---0.5) g.dL^-1^, *p* = 0.009), and a greater need for red blood cell transfusion (0 (0--4) *vs*. 0 (0--0) units, *p* = 0.02).

Death in ICU occurred in 26 patients (45.6%) treated with clopidogrel and in 17 patients (29.8%) treated with ticagrelor (*p* = 0.08). ICU length of stay was 4.0 (3.0--8.0) days, with no significant difference between the two groups (*p* = 0.19).

Ticagrelor and bleeding risk {#sec016}
----------------------------

**[Table 3](#pone.0232768.t003){ref-type="table"}** and **[Table 4](#pone.0232768.t004){ref-type="table"}** show the characteristics associated with bleeding before and during ICU. Bleeding during ICU stay was significantly associated with ticagrelor treatment (74.5% *vs*. 32.8%, *p*\< 0.0001; relative risk 2.60 (1.55--4.35)), lower left ventricular ejection fraction (30 (20--40) *vs*. 40% (30--50), *p* = 0,002), mechanical ventilation within 24 hours of ICU admission (100.0% *vs*. 79.1%, *p* = 0.0008), central venous catheter (100.0% *vs*. 80.6%, *p* = 0.001), arterial catheter (95.7% *vs*. 77.6%, *p* = 0.007), ECLS (4.5% *vs*. 25.5%, *p* = 0.001), and intra-aortic balloon pump (23.4% *vs*. 9.0%, *p* = 0.03).

10.1371/journal.pone.0232768.t003

###### Characteristics associated with bleeding before and during ICU stay.

![](pone.0232768.t003){#pone.0232768.t003g}

  Variables                                                  Bleeding during ICU stay (TIMI major or minor)   *P value*              Relative risk (CI 95%)   
  ---------------------------------------------------------- ------------------------------------------------ ---------------------- ------------------------ --------------------
  Age (years)                                                63.0 (54.6--73.1)                                66.0 (58.7--73.0)      0.63                     \-
  Male gender                                                52 (77.6%)                                       31 (66.0%)             0.17                     0.72 (0.40--1.32)
  History of                                                                                                                                                  
      Hypertension                                           45 (67.2%)                                       30 (63.8%)             0.71                     0.92 (0.51--1.66)
      Diabetes mellitus                                      42 (62.7%)                                       24 (51.1%)             0.22                     0.76 (0.43--1.34)
      Smoking                                                33 (49.3%)                                       31 (66.0%)             0.08                     1.51 (0.83--2.77)
      Dyslipidemia                                           23 (34.3%)                                       16 (34.0%)             0.97                     0.99 (0.54--1.81)
      Chronic heart failure                                  22 (32.8%)                                       13 (27.7%)             0.56                     0.86 (0.46--1.64)
      Coronary artery disease                                18 (26.9%)                                       13 (27.7%)             0.93                     1.02 (0.54--1.94)
      Peripheral artery occlusive disease                    14 (20.9%)                                       4 (8.5%)               0.07                     0.50 (0.18--1.38)
      Chronic renal failure                                  8 (11.9%)                                        6 (12.8%)              0.89                     1.05 (0.44--2.46)
      Ischemic stroke                                        8 (11.9%)                                        3 (6.4%)               0.52                     0.64 (0.20--2.06)
      Body mass index \> 30kg.m^-2^                          8 (11.9%)                                        3 (6.4%)               0.52                     0.64 (0.20--2.06)
      Sleep apnea syndrome                                   4 (6.0%)                                         4 (8.5%)               0.72                     1.23 (0.44--3.43)
      Cancer                                                 3 (4.5%)                                         4 (8.5%)               0.44                     1.42 (0.51--3.96)
      Chronic obstructive pulmonary disease                  3 (4.5%)                                         4 (8.5%)               0.44                     1.42 (0.51--3.96)
      Alcoholism                                             0 (0.0%)                                         2 (4.3%)               0.17                     2.49 (0.60--10.26)
  Usual treatment                                                                                                                                             
      Oral anticoagulant                                     2 (3.0%)                                         1 (2.1%)               1                        0.80 (0.11--5.83)
      Aspirin                                                26 (38.8%)                                       18 (38.3%)             0.96                     0.99 (0.55--1.78)
      Ticagrelor                                             2 (3.0%)                                         0 (0.0%)               0.51                     NA
      Clopidogrel                                            10 (14.9%)                                       9 (19.1%)              0.55                     1.18 (0.57--2.45)
  Place of initial care                                                                                                              0.32                     
      Outside hospital                                       37 (55.2%)                                       31 (66.0%)                                      1.00
      In hospital, emergency department                      14 (20.9%)                                       10 (21.2%)             0.91 (0.56--1.51)        
      In hospital, other department                          16 (23.9%)                                       6 (12.8%)              0.60 (0.29--1.22)        
  Type of ACS : STEMI[\*](#t003fn002){ref-type="table-fn"}   52 (77.6%)                                       36 (76.6%)             0,9                      0.97 (0.49--1.90)
  Cardiac arrest before ICU admission                        28 (41.8%)                                       25 (53.2%)             0.23                     1.31 (0.74--2.32)
  Initial treatment                                                                                                                                           
      Aspirin                                                67 (100.0%)                                      47 (100.0%)            NA                       NA
      Unfractionated Heparin                                 12 (17.9%)                                       8 (17.0%)              0.90                     1.00 (0.47--2.15)
      Low Molecular Weight Heparin                           55 (82.1%)                                       39 (83.0%)             0.90                     1.00 (0.47--2.14)
      Glycoprotein IIb/IIIa inhibitors (tirofiban)           19 (28.4%)                                       17 (36.2%)             0.38                     1.20 (0.66--2.19)
      Ticagrelor (compared to clopidogrel)                   22 (32.8%)                                       35 (74.5%)             \<0.0001                 2.60 (1.55--4.35)
  Coronarography                                             62 (92.5%)                                       46 (97.9%)             0.40                     2.57 (0.41--16.1)
      Radial approach (compared to femoral approach)         27 (43.5%)                                       26 (57.8%)             0.15                     1.39 (0.77--2.52)
      Stent                                                  49 (79.0%)                                       41 (89.1%)             0.16                     1.62 (0.64--4.10)
      ECLS during coronarography                             1 (1.5%)                                         4 (8.5%)               0.16                     1.99 (0.71--5.56)
  At ICU admission                                                                                                                                            
      Simplified Acute Physiology Score II                   61.0 (39.0--86.0)                                62.0 (44.0--85.0)      0.91                     
      Therapeutic hypothermia                                0 (0.0%)                                         1 (2.1%)               0.41                     2.41 (0.33--17.49)
      Left ventricular ejection fraction                     0.4 (0.3--0.5)                                   0.3 (0.2--0.4)         0.002                    
  Biological parameters at ICU admission                                                                                                                      
      Hemoglobin level (g.dL^-1^)                            12.2 (10.6--13.2)                                12.5 (10.5--14.1)      0.2                      
      Platelet count (G.L^-1^)                               227.5 (199.0--276.0)                             227.0 (169.0--268.0)   1                        
      aPTT (ratio)                                           1.5 (1.3--2.4)                                   2.2 (1.3--3.7)         0.18                     
      Prothrombin (%)                                        67.0 (55.0--76.0)                                68.5 (55.0--73.0)      0.7                      
      Urea (mmol.L^-1^)                                      7.8 (5.4--14.4)                                  8.2 (4.8--11.3)        0.63                     
      Creatinine (μmol.L^-1^)                                122.0 (90.0--227.0)                              126.0 (79.0--180.0)    0.55                     
      Aspartate aminotransferase (UI.L^-1^)                  108.0 (43.0--84.0)                               175.0 (69.0--339.0)    0.91                     
      Alanine aminotransferase (UI.L^-1^)                    52.5 (28.0--119.0)                               56.0 (33.0--112.0)     0.59                     

Results are expressed as median (first and third quartile) and numbers (proportions). ACS: Acute coronary syndrome; aPTT: Activated partial thromboplastin time; ECLS: Extracorporeal life support; ICU: Intensive Care Unit; NA: Not applicable; STEMI: ST-segment elevation myocardial infarction.

\*opposite to "non-ST-segment elevation myocardial infarction".

10.1371/journal.pone.0232768.t004

###### Factors potentially associated with bleeding during ICU stay.
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  Variables                                             Total (*n* = 114)    Bleeding during ICU stay (TIMI major or minor)   *P* value            
  ----------------------------------------------------- -------------------- ------------------------------------------------ -------------------- -----------
  Epinephrine within 24 hours of admission              26 (22.8%)           17 (25.4%)                                       9 (19.1%)            0.44
  Norepinephrine within 24 hours of admission           62 (54.4%)           33 (49.3%)                                       29 (61.7%)           0.19
  Dobutamine within 24 hours of admission               43 (37.7%)           22 (32.8%)                                       21 (44.7%)           0.2
  Mechanical ventilation within 24 hours of admission   100 (87.7%)          53 (79.1%)                                       47 (100.0%)          0.0008
  ECLS                                                  15 (13.2%)           3 (4.5%)                                         12 (25.5%)           0.001
      ECLS delay after ICU admission (days)             1.0 (0.0--1.0)       0.0 (0.0--1.0)                                   1.0 (0.0--1.0)       0.42
  Central venous catheter                               101 (88.6%)          54 (80.6%)                                       47 (100.0%)          0.001
  Dialysis catheter                                     31 (27.2%)           18 (26.9%)                                       13 (27.7%)           0.93
  Electrical pacing                                     6 (5.3%)             3 (4.5%)                                         3 (6.4%)             0.69
  Arterial catheter (excluding angiography catheter)    97 (85.1%)           52 (77.6%)                                       45 (95.7%)           0.007
  Intra-aortic balloon pump                             17 (14.9%)           6 (9.0%)                                         11 (23.4%)           0.03
  Proton pump inhibitor                                 108 (94.7%)          61 (91.0%)                                       47 (100.0%)          0.04
  Outcomes during ICU stay                                                                                                                         
      Minimum hemoglobin level (g.dL^-1^)               9.1 (7.7--11.2)      10.7 (8.8--12.0)                                 8.0 (7.1--9.1)       \<0.0001
      Hemoglobin variation since admission (g.dL^-1^)   -2.0 (-4.1 ---0.8)   -1.3 (-2.1 ---0.4)                               -4.4 (-6.1 ---3.1)   \<0.0001
      Red blood cell transfusion                        38 (33.3%)           8 (11.3%)                                        30 (63.3%)           \< 0.0001
      Total red blood cell transfusion (units)          0.0 (0.0--2.0)       0.0 (0.0--0.0)                                   2.0 (0.0--6.0)       \<0.0001
      Platelet transfusion                              7 (6.1%)             0 (0.0%)                                         7 (14.9%)            0.001
      Total platelet transfusion (units)                0.0 (0.0--0.0)       0.0 (0.0--0.0)                                   0.0 (0.0--0.0)       0.05
      Plasma transfusion                                6 (5.3%)             0 (0.0%)                                         6 (12.8%)            0.004
      Total plasma transfusion (units)                  0.0 (0.0--0.0)       0.0 (0.0--0.0)                                   0.0 (0.0--0.0)       0.05
      ICU length of stay (days)                         4.0 (3.0--8.0)       3.0 (1.0--5.0)                                   8.0 (4.0--15.0)      \<0.0001
      Death in ICU                                      43 (37.7%)           26 (38.8%)                                       17 (36.2%)           0.78

Results are expressed as median (first and third quartile) and numbers (proportions). ECLS: Extracorporeal life support; ICU: Intensive Care Unit.

While bleeding during ICU stay was significantly associated with greater ICU length of stay (8.0 (4.0--15.0) *vs*. 3.0 (1.0--5.0) days, *p*\< 0.0001), it was not significantly associated with ICU mortality (36.2% *vs*. 38.8, *p* = 0.78).

Discussion {#sec017}
==========

To our knowledge, this is the first study to specifically compare the bleeding risk of ticagrelor and clopidogrel in ICU patients with ACS. A study prior to ours compared the bleeding risk on prasugrel and clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. The bleeding defined by combined TIMI bleedings at 30-days occurred in 52% on prasugrel group and in 37.1% on clopidogrel group (*p* = 0.09) \[[@pone.0232768.ref019]\]. A second study, consisting of a post hoc analysis, focused on the comparison of patients on clopidogrel *vs*. ticagrelor or prasugrel in patients with acute myocardial infarction complicated by cardiogenic shock. No significant difference was found regarding the secondary endpoint for bleeding events at 12-months. Unfortunately, in this study, only 18 patients treated with ticagrelor were included (and 93 patients treated with prasugrel); the follow-up was over a year and did not focus on the specific period of stay in ICU, as in our study \[[@pone.0232768.ref020]\].

Many studies of large cohorts conducted outside the ICU have reported an increased bleeding risk of ticagrelor compared to clopidogrel, despite an overall improvement in mortality \[[@pone.0232768.ref002],[@pone.0232768.ref003]\]. The PLATO study, in which patients were followed for a period of 13 months, found that the superiority of ticagrelor in cardiovascular events was apparent within 30 days of treatment initiation and persisted throughout the study period, whereas most bleeding occurred after 30 days of treatment \[[@pone.0232768.ref003]\]. In our study of critically ill patients with severe forms of ACS, all bleeding events were observed early in the study, the median ICU length of stay being 4 (3--8) days.

A post-hoc study using data from the PLATO cohort subdivided the groups of patients treated with ticagrelor and clopidogrel according to the Killip classification (previous Heart Failure (HF) *vs*. clinical signs of HF on admission (Killip class II and III) *vs*. no HF (Killip class I) \[[@pone.0232768.ref021]\]. Patients in the ticagrelor group were found to have a lower risk of composite ischemic endpoint than patients in the clopidogrel group, regardless of HF status (hazard ratio (HR) 0.87 (95% CI: 0.73--1.03) in patients with HF and HR 0.84 (95% CI: 0.75--0.93) in patients with no HF, *p* = 0 .76). Moreover, no differences in major bleeding were observed between the two groups, again regardless of HF status (HR 1.08 (95% CI: 0.87--1.34)) \[[@pone.0232768.ref022]\]. The difference between these and our results may be explained by the fact that Killip class IV patients (*i*.*e*., cardiogenic shock---hypotension (systolic \< 90 mm Hg) with signs of peripheral vasoconstriction (oliguria, cyanosis, sweating)) were excluded from this study and not in ours. Our patients were more critically ill and, consequently, required intensive care which put them at a much higher risk of bleeding.

A retrospective study of 81 cardiac surgery patients reported an increased risk of bleeding in patients treated with aspirin and ticagrelor compared to patients treated with aspirin and clopidogrel \[[@pone.0232768.ref023]\]. This study also found greater perioperative blood loss, an increased use of blood components, and more frequent recourse to surgical revision for postoperative bleeding in patients treated with ticagrelor. Coronary artery bypass grafting is sometimes urgently required in the initial care of ACS. In our study, we excluded those patients, to focus on the non-CABG related bleeding risk in ICU. Nevertheless, those patients may require intensive care, and the bleeding risk of a dual antiplatelet therapy by aspirin and ticagrelor in this context is yet to be determined.

The management of severe bleeding in patients treated with ticagrelor remains challenging. Platelet transfusion, which is normally performed to reverse the effects of antiplatelet drugs, has been found to be inefficient in the first 24 hours in ticagrelor-treated patients, likely because circulating ticagrelor and its active metabolite (whose half-lives are 9 and 12 hours, respectively) inhibit fresh platelets \[[@pone.0232768.ref024]--[@pone.0232768.ref027]\]. A specific antidote to ticagrelor is currently being researched to address this problem \[[@pone.0232768.ref028]\]. Finally, the transition from clopidogrel to ticagrelor is the only switch between P2Y12 inhibitors that has been investigated in a trial powered for clinical endpoint; efficacy and safety of ticagrelor were not affected by previous clopidogrel exposure \[[@pone.0232768.ref002]\]. While many studies concerning switching from ticagrelor to clopidogrel have been conducted, this practice is discouraged due to a lack of safety/efficacy data \[[@pone.0232768.ref004],[@pone.0232768.ref029]--[@pone.0232768.ref031]\].

Our study focused on the intensive care management of 155 ICU patients diagnosed with severe forms of ACS. After propensity score matching, 57 patients treated with ticagrelor were compared to 57 patients treated with clopidogrel. All of our study patients were critically ill, as evidenced by the SAPS II (61.5 (41.0--85.0)) and by other indicators such as the rate of cardiac arrest before ICU admission (46.5%) or the use of ECLS during ICU stay (13.2%). As expected, intensive care management of these patients required the use of invasive techniques: for example, a central venous catheter was inserted in almost 90% of patients and a dialysis catheter in more than 25% of patients.

Our analysis of the primary outcome yielded interesting results. The first was the high occurrence of bleeding events (64%), which was estimated using a clinically relevant definition of major and minor bleeding derived from the TIMI classification. This finding was confirmed by the significant variation in hemoglobin levels and the significant use of red blood cell transfusion. In fact, bleeding complications are a frequent and serious occurrence in ICU. Accordingly, the occurrence of TIMI major and minor bleeding in our study was 61.4% and 21.0%, respectively, in marked contrast with the results of the PLATO study, in which the occurrence of TIMI major and minor bleeding was 11.1% for the ticagrelor group and 10.9% for the clopidogrel group.

Another interesting finding of our study was that in the ICU setting, the relative risk of bleeding occurrence in ACS patients treated with ticagrelor compared to clopidogrel is very high (HR 2.60 (1.55--4.35)). In fact, of all the parameters studied, only invasive medical techniques (*i*.*e*., ECLS, venous and arterial catheter, and mechanical ventilation) were significantly associated with bleeding. While this finding is not new, it reinforces the observation that bleeding is more prevalent in ICU.

Our analysis of secondary outcomes also yielded interesting results. As regards ICU mortality, death occurred in 26 (45.6%) patients treated with clopidogrel *vs*. 17 (29.8%) patients treated with ticagrelor---a difference that was not statistically significant (*p* = 0.08). Given the risk of serious bleeding associated with ticagrelor, we had expected this treatment to be associated with increased mortality. Yet, not only was this not the case, but we actually found the opposite tendency. Two hypotheses can be made to explain this finding. The first is that the patients treated with clopidogrel were more critically ill than those treated with ticagrelor, the SAPS II being 69.0 (46.0--88.0) for the clopidogrel group and 60.0 (38.0--80.0) for the ticagrelor group (*p* = 0.03). It should be recalled that the SAPS II was not included in the propensity score: the former is calculated in the first 24 hours in ICU, whereas the latter relates to the period preceding treatment selection. The second hypothesis is that the increased bleeding risk associated with ticagrelor is offset by the early cardiovascular benefits of this treatment; the wide inter individual variability in the pharmacodynamic response to clopidogrel, linked to several factors, including genotype polymorphisms, could support this hypothesis \[[@pone.0232768.ref032],[@pone.0232768.ref033]\]. We cannot conclude on this, however, because while it may be true that ticagrelor is more effective than clopidogrel (as frequently reported in the literature), the relative efficacy of ticagrelor was not the focus of our study \[[@pone.0232768.ref002]\].

Our study has several limitations. The first limitation is the retrospective and monocentric nature of the study, which prevented us from concluding on the existence of a causal link between ticagrelor and increased bleeding risk. However, our use of a high-level methodology, lends robustness to our results. It should nevertheless be noted that propensity score matching may have led us to omit some of the factors related to the initial choice of antiplatelet therapy.

Finally, our study cannot suggest a contraindication to ticagrelor in the management of ICU patients with ACS. Our analysis focused on bleeding complications in the initial phase of ACS management, when in fact the final choice between clopidogrel and ticagrelor must be made based on long-term evaluation of treatment efficacy. There is a major lack of prospective randomized study in this sub-category of patient with a severe form of ACS.

Conclusions {#sec018}
===========

Bleeding complications are frequent and serious in ICU patients with ACS. A dual antiplatelet therapy of aspirin and ticagrelor is associated with a higher risk of bleeding compared to a dual antiplatelet therapy of aspirin and clopidogrel. More studies on this topic are urgently needed to help improve the intensive care management of patients with severe forms of ACS.
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